Elmar Schnee has been named the new executive chairman of EnteroBiotix, a company that claims to be pioneering the future of modern medicine through microbiome-modulating therapeutics. 17 July 2023
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the global sector trade body, today announced a new line up for its chief executive (CEO) leadership team for the coming two years. 12 July 2023
Privately-held Italian drugmaker Chiesi Farmaceutici has appointed Alessandro Chiesi as chairman of the Chiesi Group. Additionally, it said that Maria Paola Chiesi becomes vice chair. 7 July 2023
Privately-held Danish dermatology specialist LEO Pharma has appointed Kreesten Meldgaard Madsen as chief development officer and, effective Tuesday, he joined LEO Pharma’s global leadership team (GLT). 21 June 2023
The appointment of a new chief executive at immune-mediated disease specialist Veralox Therapeutics coincides with a fresh investment of $24 million from new and existing backers. 20 June 2023
Texas, USA-based drug developer Reata Pharmaceuticals says that the US Food and Drug Administration (FDA) accepted for filing the Prior Approval Supplement (PAS) to update the drug substance specification for Skyclarys (omaveloxolone). 16 June 2023
Canada-based eye health specialist Bausch + Lomb has announced a reshaping of its executive leadership team, including the elevation of all business unit heads. 2 June 2023
The leading trade body for the British pharmaceutical industry has appointed a new president, current Pfizer UK managing director Susan Rienow. 25 May 2023
As part of its growth strategy, UK biotech Fixed Phage, a developer of proprietary, anti-infective technologies, today announced the appointment Dr Neil Clelland as its new chief executive (CEO). 24 May 2023
As a next step in focusing on the US market, the board of Swedish diagnostic testing and precision medicines firm Immunovia AB has decided to appoint Jeff Borcherding, until now president of Immunovia’s US operation, as global chief executive 2 May 2023
UK-based iron deficiency specialist Shield Therapeutics today revealed that Andy Hurley will be joining the firm’s executive team as chief commercial officer (CCO), effective April 10, 2023. 5 April 2023
Karim Mikhail is to resign as president and chief executive of Amarin Corp, the Ireland-headquartered fish oil-based heart drug specialist, according to a US Securities and Exchange Commission filing. 3 April 2023
Karen Harrison has been named chief operating officer of the Therapeutics Division at Avacta, a UK-based life sciences company developing targeted oncology drugs and diagnostics. 29 March 2023
Portugal’s largest drugmaker BIAL is boosting its management team with the addition of a former big pharma exec, Max Bricchi, as its chief commercial officer, who will also join the executive board. 23 March 2023
To achieve its goal of being a leader in medical dermatology, Denmark’s LEO Pharm today announced – in early 2023 - a significant shift in R&D to a research model, which aims at driving the early-stage pipeline with externally sourced innovation. 14 March 2023
Hidden among the detail of Spanish drugmaker Almirall’s financial results on Monday was news about the leadership of the Barcelona-based company. 21 February 2023
Florida, USA-based Axogen, which is developing and marketing innovative solutions for peripheral nerve injuries, has announced the appointment of Jens Schroeder Kemp to the newly created role of chief marketing officer. 15 February 2023
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Lykos Therapeutics has announced a reorganization to best support the company as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults. 16 August 2024
German infectious disease specialist AiCuris Anti-infective Cures has announced the appointment of Cynthia Wat as chief medical officer (CMO). 30 July 2024
Ophirex, a registered public benefit corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, has announced the appointment of Jeremy Gowler as chief executive. 15 July 2024
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024